8-K: TruBridge Reports Q3 2025 Results, Boosts Profitability

TruBridge, a healthcare technology provider, announced solid third-quarter 2025 revenue growth and significant profitability expansion, alongside revised full-year guidance.

Summary

• Total revenue for Q3 2025 reached $86.1 million, an increase from $84.7 million in Q3 2024.
• Recurring revenue represented a strong 94% of total revenue in Q3 2025.
• GAAP net income was $5.6 million in Q3 2025, a significant improvement from a net loss of $9.1 million in Q3 2024.
• Non-GAAP net income for Q3 2025 was $12.8 million, compared to a net loss of $3.1 million in Q3 2024.
• Adjusted EBITDA increased to $16.3 million in Q3 2025 from $14.7 million in Q3 2024, achieving a 19% margin.
• Total bookings for Q3 2025 were $15.5 million, down from $21.0 million in Q3 2024.
• Full-year 2025 total revenue guidance was revised to $345 million to $348 million, from a previous range of $345 million to $350 million.
• Full-year 2025 Adjusted EBITDA guidance was raised to $65 million to $68 million, from a previous range of $62 million to $67 million.
• The company made leadership enhancements, including hiring a Chief Business Officer and a head of India operations to drive growth and optimize performance.

Sentiment

Score: 8

Explanation: The company demonstrated strong profitability improvements, positive GAAP and Non-GAAP net income reversals, and increased Adjusted EBITDA. While bookings declined, the overall financial health and management's strategic initiatives, including leadership enhancements and offshore transition, point to a positive trajectory. The raised Adjusted EBITDA guidance for the full year further supports a strong sentiment.

Positives

• Total revenue increased to $86.1 million in Q3 2025 from $84.7 million in Q3 2024, demonstrating growth.
• GAAP net income significantly improved to $5.6 million in Q3 2025 from a net loss of $9.1 million in Q3 2024, indicating a strong return to profitability.
• Non-GAAP net income turned positive at $12.8 million in Q3 2025 compared to a net loss of $3.1 million in Q3 2024, reflecting enhanced operational performance.
• Adjusted EBITDA increased to $16.3 million in Q3 2025 from $14.7 million in Q3 2024, achieving a healthy 19% margin.
• Recurring revenue constitutes a strong 94% of total revenue, indicating a stable and predictable business model.
• Full-year 2025 Adjusted EBITDA guidance was raised to $65 million to $68 million from $62 million to $67 million, signaling management's increased confidence in future profitability.
• Cash and cash equivalents increased to $19.920 million as of September 30, 2025, from $12.324 million at December 31, 2024, improving liquidity.
• Net cash provided by operating activities increased to $28.107 million for the nine months ended September 30, 2025, from $21.839 million in the prior year, demonstrating strong cash generation.

Negatives

• Total bookings decreased to $15.5 million in Q3 2025 from $21.0 million in Q3 2024, indicating a slowdown in new contract acquisition.
• Financial Health revenue slightly decreased to $54.5 million in Q3 2025 from $54.7 million in Q3 2024.
• Full-year 2025 total revenue guidance was slightly narrowed on the high end, revised to $345 million to $348 million from $345 million to $350 million.
• Net new bookings for Financial Health significantly declined to $1.635 million in Q3 2025 from $6.112 million in Q3 2024.
• Patient Care subscription revenue decreased to $2.055 million in Q3 2025 from $3.448 million in Q3 2024.

Risks

• Saturation of the target market and hospital consolidations could limit growth opportunities.
• Unfavorable economic or market conditions may cause a decline in spending for information technology and services.
• Significant legislative and regulatory uncertainty in the healthcare industry poses compliance and operational risks.
• Exposure to liability for failure to comply with regulatory requirements.
• Challenges in the transition to a subscription-based recurring revenue model and modernization of technology.
• Competition with companies that have greater financial, technical, and marketing resources.
• Potential future acquisitions may be expensive, time-consuming, and subject to inherent risks.
• Difficulty in attracting and retaining qualified personnel in a global workforce.
• Disruption from periodic restructuring of the sales force.
• Slower than anticipated development of the market for Financial Health services.
• Potential inability to properly manage growth in new markets the company may enter.
• Potential failure to effectively implement a new enterprise resource planning software solution.
• Exposure to numerous and often conflicting laws, regulations, policies, standards, or other requirements through domestic and international business activities.
• Potential litigation and investigations.
• Risks associated with the use of offshore third-party resources.
• Competitive and litigation risk related to the use of artificial intelligence.
• Potential failure to develop new products or enhance current products that keep pace with market demands.
• Failure of products to provide accurate and timely information for clinical decision-making.
• Breaches of security and viruses in systems resulting in customer claims and harm to reputation.
• Failure to maintain customer satisfaction through new product releases free of undetected errors or problems.
• Failure to convince customers to migrate to current or future releases of products.
• Failure to maintain margins and service rates.
• Increase in the percentage of total revenues represented by service revenues, which have lower gross margins.
• Exposure to liability in the event of providing inaccurate claims data to payors.
• Exposure to liability claims arising out of the licensing of software and provision of services.
• Dependence on licenses of rights, products, and services from third parties.
• Failure to protect intellectual property rights.
• Exposure to significant license fees or damages for intellectual property infringement.
• Interruptions in power supply and/or telecommunications capabilities.
• Potential inability to secure additional financing on favorable terms to meet future capital needs.
• Substantial indebtedness and the ability to incur additional indebtedness in the future.
• Pressures on cash flow to service outstanding debt.
• Restrictive terms of the credit agreement on current and future operations.
• Changes in and interpretations of financial accounting matters that govern the measurement of performance.
• Significant charges to earnings if goodwill or intangible assets become impaired.
• Fluctuations in quarterly financial performance due to various factors.
• Volatility in stock price.
• Failure to maintain effective internal control over financial reporting.
• Inherent limitations in internal control over financial reporting.
• Vulnerability to significant damage from natural disasters.
• Market risks related to interest rate changes.
• Potential material adverse effects due to macroeconomic conditions.
• The company does not anticipate paying dividends on its common stock.
• Actions of activist stockholders against the company.
• Other risk factors described from time to time in public releases and reports filed with the Securities and Exchange Commission.

Future Outlook

For the fourth quarter of 2025, TruBridge expects total revenue between $86 million and $89 million, and Adjusted EBITDA between $16.5 million and $19.5 million. For the full year 2025, the company revised its total revenue guidance to $345 million to $348 million (from $345 million to $350 million) and raised its Adjusted EBITDA guidance to $65 million to $68 million (from $62 million to $67 million).

Management Comments

• "In the third quarter, we delivered solid revenue and achieved a 19% Adjusted EBITDA margin, further expanding profitability in a sustainable way that will allow for continued improvement over time."
• "We've made significant progress over the past two years enhancing the financial performance of our business, meaningfully expanding margins, generating free cash flow, and de-levering the balance sheet."
• "Now that we successfully built a solid foundation and have proven our ability to execute on our financial objectives, we are applying the same disciplined approach to improving our performance across the business."
• "We continue to make leadership enhancements to ensure we have the most effective people on board. Most recently we hired a Chief Business Officer to oversee client-centered excellence, sales and marketing to drive growth."
• "We have continued to bring in the right leadership, including the head of India operations to lead the restart of our offshore transition process."
• "Together, these improvements will optimize our performance over time allowing us to achieve our strategic business objectives and deliver even greater EBITDA margins and free cash flow in the years to come."

Industry Context

TruBridge operates in the specialized and critical sector of revenue cycle management and healthcare technology for rural and community healthcare organizations. The company's focus on expanding profitability, generating free cash flow, and de-levering the balance sheet suggests a strategic response to potential industry pressures or a move towards greater financial stability, which is crucial for providers serving often underserved rural markets. The leadership enhancements and restart of offshore transition indicate efforts to optimize operations and potentially gain cost efficiencies in a competitive landscape, aligning with broader trends of healthcare providers seeking efficiency and cost reduction through technology and outsourced services.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to improved profitability, increased Adjusted EBITDA, and raised full-year EBITDA guidance, potentially leading to increased share value.
• Employees: Potential impact from leadership enhancements and the restart of offshore transition process, which could involve new roles or shifts in operational focus.
• Customers: Focus on "client-centered excellence" and "sales and marketing to drive growth" suggests efforts to improve customer experience and expand service offerings.
• Creditors: Positive impact from de-levering the balance sheet and generating free cash flow, improving the company's ability to service its debt.

Next Steps

• Hold a conference call and live webcast on November 7, 2025, to discuss Q3 2025 results.
• Continue leadership enhancements and apply a disciplined approach to improving performance across the business.
• Lead the restart of the offshore transition process.
• Fully transition to the Annual Contract Value (ACV) bookings methodology in 2026.

Key Dates

Recommendation

The company has demonstrated a significant turnaround in profitability, moving from net losses to positive net income on both GAAP and Non-GAAP bases. Adjusted EBITDA has grown, and the full-year EBITDA guidance has been raised, indicating strong operational performance and management's confidence. While bookings saw a decline, the high percentage of recurring revenue (94%) provides stability. Strategic leadership hires and the focus on offshore transition suggest further efficiency gains and growth initiatives. The de-leveraging of the balance sheet and generation of free cash flow also point to improved financial health, making it an attractive investment.

Keywords

Healthcare Technology, Revenue Cycle Management, RCM, EHR, Electronic Health Records, Rural Healthcare, Community Healthcare, Financial Health, Patient Care, Adjusted EBITDA, GAAP Net Income, Bookings, TruBridge, TBRG